Eilean Therapeutics LLC has announced the acquisition of Ness Therapeutics Inc. in an all-equity transaction, including Ness’ best-in-class tyrosine-protein phosphatase non-receptor type 2 (PTPN2) inhibitors with application in immuno-oncology.

Scientists from Sun Yat-sen University Cancer Center (SYSUCC) and affiliated organizations have reported data from a study that assessed the role of discs large-associated protein 5 (DLGAP5) in lung adenocarcinoma (LUAD).

Researchers from Nankai University have discovered a novel nitroaromatic nannocystin with promising activity against colorectal cancer (CRC).

Researchers from Nanjing University and affiliated organizations have published the outcomes of a study that aimed to investigate the role of cadherin 4 (CDH4) in the metastatic cascade of papillary thyroid cancer (PTC).

Children’s Hospital Los Angeles (CHLA) has received a multiyear $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors. The CIRM funding will support further CHLA research into harnessing chimeric antigen receptor (CAR) T-cell therapy.

Scientists from First Affiliated Hospital Bengbu Medical College and affiliated organizations have studied the role of the RNA-binding ubiquitin ligase MEX3C in lung adenocarcinoma (LUAD).

C4 Therapeutics Inc. has entered into a license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins.